- Home
- MPV vs FENC Comparison
MPV vs FENC Comparison
Compare MPV & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPV | FENC |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 230.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | MPV | FENC |
|---|---|---|
| Price | $16.25 | $10.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 11.2K | ★ 263.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ $9.85 | $1,075.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.65 | $5.65 |
| 52 Week High | $21.00 | $11.31 |
Technical Indicators
Market Signals| Indicator | MPV | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 62.20 |
| Support Level | $15.91 | $7.40 |
| Resistance Level | $17.57 | $10.45 |
| Average True Range (ATR) | 0.53 | 0.51 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 19.94 | 66.73 |
Price Performance
Historical ComparisonAbout MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.